Audit on Deucravacitinib for treating moderate to severe plaque psoriasis against NICE Guidelines (ESDR 2026) - Oct 5, 2026 - Abstract #587; "However, a significant gap was identified in 16-week outcome monitoring, with only 48% of patients having documented PASI and DLQI scores. The main limitation of this audit is incomplete documentation, which may underestimate true clinical response thus limiting full evaluation of treatment effectiveness"
Dermatology • Immunology • Plaque Psoriasis • Psoriasis
|